Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meditoxin
- Development stage
- Phase 4
- Lead developer
- Medytox
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intramuscular
01
Overview
Meditoxin is a botulinum toxin type A product developed by Medytox Inc. in South Korea. It works by temporarily blocking acetylcholine release at neuromuscular junctions, relaxing muscles to reduce wrinkles and treat various muscle-related conditions. It's used for both aesthetic purposes (reducing facial wrinkles) and therapeutic applications (treating blepharospasm, muscle spasticity, and equinus foot deformity).
- Brand names
- Meditoxin
- Other names
- BotuliftCunoxNeuronoxNivobotulinumtoxinASiax
02
Targets
GT1b (Ganglioside GT1b)SNAP25 (Synaptosome-associated protein 25)
Beyond the preview
Go deeper on Meditoxin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meditoxin.